Clementia Announces Presentation at the J.P. Morgan 36th Annual Healthcare Conference
MONTREAL, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardins, Ph.D., chief executive officer and founder of Clementia, will present at the J.P. Morgan 36th Annual Healthcare Conference on Wednesday, Jan. 10, at 5:00 p.m. PT at the Westin St. Francis in San Francisco.
A webcast of the presentation will be available in the Investor Relations section of the company's website at www.clementiapharma.com. A replay of the webcast will be available for 30 days following the presentation.
About Clementia Pharmaceuticals Inc.
Clementia is a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company’s lead candidate palovarotene, a novel RARγ agonist, is currently being evaluated in the Phase 3 MOVE Trial to treat fibrodysplasia ossificans progressiva (FOP), with additional clinical studies planned in multiple osteochondromas (MO, also known as hereditary multiple exostoses) and other diseases. For more information, please visit www.clementiapharma.com.
Investor/Media Contact:
Joseph Walewicz
Clementia Pharmaceuticals Inc.
+1-514-940-1080
Chelcie Lister
THRUST Investor Relations
+1-910-777-3049
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
